Why Halozyme Therapeutics (HALO) Is Down 7.9% After Acquisition-Driven Q4 Loss And 2026 Outlook Reaffirmation

Simply Wall St

Thu, February 19, 2026 at 12:13 PM GMT+9

In this article:

HALO

-9.01%

In February 2026, Halozyme Therapeutics reported Q4 2025 revenue of US$451.77 million and full‑year revenue of US$1.40 billion, but a quarterly net loss of US$141.59 million driven by acquisition-related impairment and IPR&D charges, while reiterating 2026 revenue guidance of US$1.71 billion to US$1.81 billion.

Alongside strong ENHANZE-driven revenue momentum and recent deals for new hyperconcentration drug delivery technologies, management signaled plans to keep using robust cash flow for disciplined M&A and at least three new licensing agreements in 2026, aiming to broaden royalty and high‑margin revenue sources.

We’ll now examine how Halozyme’s acquisition-fueled expansion of its drug delivery portfolio affects the existing investment narrative around ENHANZE-driven royalties.

Invest in the nuclear renaissance through our list of 85 elite nuclear energy infrastructure plays powering the global AI revolution.

Halozyme Therapeutics Investment Narrative Recap

To own Halozyme, you need to believe ENHANZE and the newer hyperconcentration platforms can support durable, high margin royalty and licensing revenue, even as partners face pricing and biosimilar pressures. The latest Q4 2025 results, with strong top line but a loss driven by acquisition related charges, do not appear to change the near term focus on ENHANZE uptake as the key catalyst or on concentration in a few major partners as the main risk.

The most relevant recent update is management’s reaffirmed 2026 revenue guidance of US$1.71 billion to US$1.81 billion alongside the Q4 release. For me, that guidance sits at the center of the current catalyst debate, because it ties together ENHANZE driven growth with expectations for the newly acquired drug delivery technologies, while also framing how much headroom Halozyme may have if large partnered products face reimbursement or biosimilar related headwinds.

Yet behind that solid revenue outlook, investors should still be aware of the concentration risk if one or more key ENHANZE partners…

Read the full narrative on Halozyme Therapeutics (it’s free!)

Halozyme Therapeutics’ narrative projects $2.0 billion revenue and $1.1 billion earnings by 2028.

Uncover how Halozyme Therapeutics’ forecasts yield a $77.12 fair value, a 5% upside to its current price.

Exploring Other Perspectives

HALO 1-Year Stock Price Chart

Some of the lowest estimate analysts took a much harsher view, arguing that ENHANZE dependence could backfire even as they were penciling in about US$2.1 billion of revenue and US$1.1 billion of earnings by 2028, so if you own or are considering Halozyme it is worth weighing that more cautious scenario against the recent acquisitions and guidance reaffirmation.

Story continues  

Explore 9 other fair value estimates on Halozyme Therapeutics - why the stock might be worth over 2x more than the current price!

Decide For Yourself

Don’t just follow the ticker - dig into the data and build a conviction that’s truly your own.

A great starting point for your Halozyme Therapeutics research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.

Our free Halozyme Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Halozyme Therapeutics' overall financial health at a glance.

Seeking Other Investments?

Our daily scans reveal stocks with breakout potential. Don’t miss this chance:

Capitalize on the AI infrastructure supercycle with our selection of the 34 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Uncover the next big thing with 31 elite penny stocks that balance risk and reward.

Find 53 companies with promising cash flow potential yet trading below their fair value.

_ This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._

Companies discussed in this article include HALO.

Have feedback on this article? Concerned about the content? Get in touch with us directly._ Alternatively, email editorial-team@simplywallst.com_

Terms and Privacy Policy

Privacy Dashboard

More Info